04/17/2026
Urolithin A: The $1.14B Market Opportunity Your Brand Can't Ignore
The Urolithin A market was valued at $1.14 billion in 2025 and is projected to reach $2.55 billion by 2032, growing at a CAGR of 12.14% . The global Urolithin A supplement market is set to expand from $532 million (2025) to $889 million (2031) at 8.9% CAGR-1-2.
Why the explosive growth? Consumers are increasingly demanding evidence-based ingredients for healthy aging, cellular energy, and muscle vitality. Urolithin A, a gut-derived postbiotic metabolite of ellagitannins found in pomegranates, berries, and walnuts, is uniquely positioned to meet this demand-.
🔬 The science: Preclinical studies have shown that Urolithin A induces mitophagy both in vitro and in vivo, preventing age-associated mitochondrial dysfunction, improving muscle function, and enhancing exercise capacity-10. 2025 clinical trials demonstrated its potential to support immune resilience, endurance recovery, and cardiovascular health-28.
✅ The formulation advantage: Unlike traditional ellagitannin sources, direct Urolithin A supplementation bypasses gut microbiome variability. Approximately 10% of individuals are classified as urolithin non producers — meaning they cannot convert ellagitannins into bioactive Urolithin A at all-10. Direct supplementation ensures 100% user efficacy regardless of microbiome composition.
💊 Formulation formats: Capsules | Softgels | Powder Sticks | Gummies | RTD Beverages
📦 We supply pharmaceutical-grade Urolithin A (≥98% purity) with full traceability, batch level CoAs, and FDA GRAS compliance.